Doximity (DOCS) reported a 20% increase in top-line growth for fiscal 2025 following the launch of several AI-powered tools like Doximity GPT, which streamlines clinician workflows. The company is positioned to grow at approximately twice the market rate, with over 80% of U.S. physicians using its platform. While management emphasized strong adoption of these tools during an earnings call, they did not disclose specific revenue impacts, indicating that monetization might still be in its development phase.
Shares of Doximity have increased by 6.9% year-to-date, compared to the industry’s growth of 28%. The company has a forward 12-month price-to-sales ratio of 16.9, significantly higher than the industry average of 6. The Zacks Consensus Estimate suggests a 2.8% improvement in earnings per share for fiscal 2026. Doximity’s reliance on pharmaceutical marketing dollars raises questions about future revenue stability, even as AI tools enhance user engagement.
